Rational coformer or solvent selection for pharmaceutical cocrystallization or desolvation

Journal of Pharmaceutical Sciences

Volumn 101, Issue 10, 2012, Pages 3687-3697

  Abramov, Yuriy A ^a   Loschen, Christoph ^b   Klamt, Andreas ^b,c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b COSMOlogic GmbH and Co KG ^*  (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Cocrystals; COSMO RS; Crystal engineering; Crystallization; Desolvation; Excess enthalpy; In silico modeling; Solubility; Solvates

Indexed keywords

AXITINIB; FUNGICIDE; SOLVENT; THIOPHANATE METHYL;

ACCURACY; ARTICLE; COMPUTER PROGRAM; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; ENTHALPY; PHARMACEUTICS; PREFORMULATION; PROPENSITY SCORE; SCREENING; SOLVATE; SOLVATION; THERMODYNAMICS;

EID: 84865384434     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23227     Document Type: Article

References (60)

1. Aakeröy CB, Salmon DJ. 2005. Building co-crystals with molecular sense and supramolecular sensibility. CrystEngCommun 7:439-448.
2. Jones W, Motherwell WS, Trask AV. 2006. Pharmaceutical co-crystals: An emerging approach to physical property enhancement. MRS Bull 31:875-879.
3. Schultheiss N, Newman A. 2009. Pharmaceutical co-crystals and their physicochemical properties. Cryst Growth Des 9:2950-2967.
4. Variankaval N, Wenslow R, Murry J, Hartman R, Helmy R, Kwong E, Clas S-D, Dalton C, Santos I. 2006. Preparation and solid-state characterization of nonstoichiometric co-crystals of a phosphodiesterase-IV inhibitor and l-tartaric acid. Cryst Growth Des 6:690-700.
5. McNamara D, Childs S, Giordano J, Iarriccio A, Cassidy J, Shet M, Mannion R, O'Donnell E, Park A. 2006. Use of a glutaric acid co-crystal to improve oral bioavailability of a low solubility API. Pharm Res 23:1888-1897.
6. Trask AV. 2007. An overview of pharmaceutical co-crystals as intellectual property. Mol Pharm 4:301-309.
7. Vippagunta SR, Brittain HG, Grant DJ. 2001. Crystalline solids. Adv Drug Deliv Rev 48:3-26.
8. Trask AV, Motherwell WDS, Jones W. 2004. Solvent-drop grinding: Green polymorph control of co-crystallisation. Chem Commun 890-891.
9. Delori A, Friscic T, Jones W. 2012. The role of mechanochemistry and supramolecular design in the development of pharmaceutical materials. CrystEngComm 14:2350-2362.
10. Blagden N, Berry DJ, Parkin A, Javed H, Ibrahim A, Gavan PT, De Matos LL, Seaton CC. 2008. Current directions in co-crystal growth. New J Chem 32:1659-1672.
11. Basavoju S, Boström D, Velaga S. 2008. Indomethacin-saccharin co-crystal: Design, synthesis and preliminary pharmaceutical characterization. Pharm Res 25:530-541.
12. Zhang GG, Henry RF, Borchardt TB, Lou X. 2007. Efficient co-crystal screening using solution-mediated phase transformation. J Pharm Sci 96:990-995.
13. Issa N, Karamertzanis PG, Welch GWA, Price SL. 2009. Can the formation of pharmaceutical co-crystals be computationally predicted? I. Comparison of lattice energies. Cryst Growth Des 9:442-453.
14. Karamertzanis PG, Kazantsev AV, Issa N, Welch GW, Adjiman CS, Pantelides CC, Price SL. 2009. Can the formation of pharmaceutical co-crystals be computationally predicted? 2. Crystal structure prediction. J Chem Theory Comput 5:1432-1448.
15. Cruz-Cabeza AJ, Day GM, Jones W. 2008. Towards prediction of stoichiometry in crystalline multicomponent complexes. Chem Eur J 14:8830-8836.
16. Mohamed S, Tocher DA, Price SL. 2011. Computational prediction of salt and co-crystal structures-Does a proton position matter? Int J Pharm 418:187-198.
17. Desiraju GR. 1995. Supramolecular synthons in crystal engineering-A new organic synthesis. Angew Chem Int Ed Engl 34:2311-2327.
18. Shattock TR, Arora KK, Vishweshwar P, Zaworotko MJ. 2008. Hierarchy of supramolecular synthons: Persistent carboxylic acid···pyridine hydrogen bonds in co-crystals that also contain a hydroxyl moiety. Cryst Growth Des 8:4533-4545.
19. Bis JA, Vishweshwar P, Weyna D, Zaworotko MJ. 2007. Hierarchy of supramolecular synthons: Persistent hydroxyl-pyridine hydrogen bonds in co-crystals that contain a cyano acceptor. Mol Pharm 4:401-416.
20. Musumeci D, Hunter CA, Prohens R, Scuderi S, McCabe JF. 2011. Virtual co-crystal screening. Chem Sci 2:883-890.
21. Allen FH, Bellard S, Brice MD, Cartwright BA, Doubleday A, Higgs H, Hummelink T, Hummelink-Peters BG, Kennard O, Motherwell WDS, Rodgers JR, Watson DG. 1979. The cambridge crystallographic data centre: Computer-based search, retrieval, analysis and display of information. Acta Crystallogr 35:2331-2339.
22. Fábián L. 2009. Cambridge structural database analysis of molecular complementarity in co-crystals. Cryst Growth Des 9:1436-1443.
23. Babu NJ, Reddy LS, Nangia A. 2007. Amide-n-oxide heterosynthon and amide dimer homosynthon in cocrystals of carboxamide drugs and pyridine n-oxides. Mol Pharm 4:417-434.
24. Mohammad MA, Alhalaweh A, Velaga SP. 2011. Hansen solubility parameter as a tool to predict co-crystal formation. Int J Pharm 407:63-71.
25. Klamt A. 2011. The COSMO and COSMO-RS solvation models. WIREs: Comput Mol Sci 1:699-709.
26. Samas B, Seadeek C, Campeta AM, Chekal BP. 2011. A thermodynamic-based approach to analyzing a highly solvating polymorphic system: The desolvation window method. J Pharm Sci 100:186-194.
27. Klamt A. 2005. COSMO-RS: From quantum chemistry to fluid phase thermodynamics and drug design. Amsterdam, the Netherlands: Elsevier Science Ltd.
28. Eckert F, Klamt A. 2010. COSMOtherm, Version C2.1, Release 01.11; COSMOlogic GmbH & Co. KG, Leverkusen, Germany.
29. Eckert F, Klamt A. 2002. Fast solvent screening via quantum chemistry: COSMO-RS approach. AIChE J 48:369-385.
30. TURBOMOLE, TURBOMOLE V6.3. A development of University of Karlsruhe and Forschungszentrum Karlsruhe GmbH, 1989-2007, TURBOMOLE GmbH, since 2007; Available at: http://www.turbomole.com.
31. Becke AD. 1988. Density-functional exchange-energy approximation with correct asymptotic behavior. Phys Rev A 38:3098-3100.
32. Perdew JP. 1986. Density-functional approximation for the correlation energy of the inhomogeneous electron gas. Phys Rev B 33:8822-8824.
33. Perdew JP. 1986. Erratum: Density-functional approximation for the correlation energy of the inhomogeneous electron gas. Phys Rev B 34:7406-7406.
34. Schäfer A, Huber C, Ahlrichs R. 1994. Fully optimized contracted Gaussian basis sets of triple zeta valence quality for atoms Li to Kr. J Chem Phys 100:5829-5835.
35. Hornig M, Klamt A. 2005. COSMOfrag: A novel tool for high-throughput ADME property prediction and similarity screening based on quantum chemistry. J Chem Inf Model 45:1169-1177.
36. Klamt A, Eckert F, Diedenhofen M. 2009. Prediction of the free energy of hydration of a challenging set of pesticide-like compounds. J Phys Chem B 113:4508-4510.
37. OMEGA. OpenEye Scientific Software, Inc. Santa Fe, New Mexico.
38. Remenar JF, Morissette SL, Peterson ML, Moulton B, MacPhee JM, Guzmán HR, Almarsson Ö. 2003. Crystal engineering of novel co-crystals of a triazole drug with 1, 4-dicarboxylic acids. J Am Chem Soc 125:8456-8457.
39. Kojima T, Tsutsumi S, Yamamoto K, Ikeda Y, Moriwaki T. 2010. High-throughput co-crystal slurry screening by use of in situ Raman microscopy and multi-well plate. Int J Pharm 399:52-59.
40. Berry DJ, Seaton CC, Clegg W, Harrington RW, Coles SJ, Horton PN, Hursthouse MB, Storey R, Jones W, Friscić T, Blagden N. 2008. Applying hot-stage microscopy to co-crystal screening: A study of nicotinamide with seven active pharmaceutical ingredients. Cryst Growth Des 8:1697-1712.
41. Cheney ML, Weyna DR, Shan N, Hanna M, Wojtas L, Zaworotko MJ. 2010. Supramolecular architectures of meloxicam carboxylic acid co-crystals, a crystal engineering case study. Cryst Growth Des 10:4401-4413.
42. Seaton CC, Parkin A. 2011. Making benzamide co-crystals with benzoic acids: The influence of chemical structure. Cryst Growth Des 11:1502-1511.
43. Karki S, Friščić T, Fábián L, Laity PR, Day GM, Jones W. 2009. Improving mechanical properties of crystalline solids by co-crystal formation: New compressible forms of paracetamol. Adv Materials 21:3905-3909.
44. Bathori NB, Lemmerer A, Venter GA, Bourne SA, Caira MR. 2011. Pharmaceutical co-crystals with isonicotinamide-vitamin b3, clofibric acid, and diclofenac-and two isonicotinamide hydrates. Cryst Growth Des 11:75-87.
45. Good DJ, Rodríguez-Hornedo N. 2009. Solubility advantage of pharmaceutical co-crystals. Cryst Growth Des 9:2252-2264.
46. Eckert F. 2006. Prediction of solubility with COSMO-RS. In Developments and applications in solubility; Letcher T, ed., Cambridge, United Kingdom: The Royal Society of Chemistry.
47. Ben-Naim A. 1987. Solvation thermodynamics. New York, New York: Plenum Press.
48. FDA website, Food Ingredients & Packaging. http://www.fda.gov/Food/FoodIngredientsPackaging/default.htm. Retrieved 22 February 2012.
49. Chemical Resolver Identifier beta4. http://cactus.nci.nih.gov/chemical/structure. Retrieved 22 February 2012.
50. Buschmann HH. 2009. EuropeanPatentApplicationEP 2 199 274 A1.
51. Oswald IDH, Allan DR, McGregor PA, Motherwell WDS, Parsons S, Pulham CR. 2002. The formation of paracetamol (acetaminophen) adducts with hydrogen-bond acceptors. Acta Crystallogr Sect B: Struct Sci 58:1057-1066.
52. Elbagerma MA, Edwards HGM, Munshi T, Scowen IJ. 2011. Identification of a new co-crystal of citric acid and paracetamol of pharmaceutical relevance. CrystEngComm 13:1877-1884.
53. Sander JR, Bučar D-K, Henry RF, Baltrusaitis J, Zhang GG, MacGillivray LR. 2010. A red zwitterionic co-crystal of acetaminophen and 2, 4-pyridinedicarboxylic acid. J Pharm Sci 99:3676-3683.
54. Cheney ML, Weyna DR, Shan N, Hanna M, Wojtas L, Zaworotko MJ. 2011. Coformer selection in pharmaceutical co-crystal development: A case study of a meloxicam aspirin co-crystal that exhibits enhanced solubility and pharmacokinetics. J Pharm Sci 100:2172-2181.
55. Tumanov NA, Myz SA, Shakhtshneider TP, Boldyreva EV. 2012. Are meloxicam dimers really the structure-forming units in the 'meloxicam-carboxylic acid' co-crystals family? Relation between crystal structures and dissolution behaviour. CrystEngComm 14:305-313.
56. Luger P, Daneck K, Engel W, Trummlitz G, Wagner K. 1996. Structure and physicochemical properties of meloxicam, a new NSAID. Eur J Pharm Sci 4:175-187.
57. Campeta AM, Chekal BP, Abramov YA, Meenan PA, Henson MJ, Shi B, Singer RA, Horspool KR. 2010. Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API. J Pharm Sci 99:3874-3886.
58. Chekal BP, Campeta AM, Abramov YA, Feeder N, Glynn PP, McLaughlin RW, Meenan PA, Singer RA. 2009. The challenges of developing an API crystallization process for a complex polymorphic and highly solvating system. Part 1. Org Process Res Dev 13:1327-1337.
59. Nauha E, Saxell H, Nissinen M, Kolehmainen E, Schäfer A, Schlecker R. 2009. Polymorphism and versatile solvate formation of thiophanate-methyl. CrystEngComm 11:2536-2547.
60. Nauha E, Ojala A, Nissinen M, Saxell H. 2011. Comparison of the polymorphs and solvates of two analogous fungicides-A case study of the applicability of a supramolecular synthon approach in crystal engineering. CrystEngComm 13:4956-4964.